Synchron was named the eighth most innovative data science company of 2026 by Fast Company, a ranking that reflects the company’s positioning as a neural data platform rather than a pure medical device maker.

The recognition follows a year in which Synchron’s U.S. COMMAND study moved from clinical feasibility to home-use validation. Patients used the Stentrode, a brain-computer interface implanted through blood vessels without open brain surgery, to control digital devices, send text messages, and compose emails from home. The study produced what the company describes as the largest United States dataset ever generated by an implanted BCI, built on more than twenty patient-years of continuously recorded brain activity.

That dataset underpins Chiral, a cognitive AI foundation model that Synchron developed with Nvidia and unveiled at GTC in 2025. Chiral trains on self-supervised neural data, learning directly from how the brain encodes intention rather than relying on labelled training sets. As more patients use the Stentrode for longer periods, the model improves, creating a feedback loop between hardware deployment and software capability.

Fast Company’s placement of Synchron in the data science category rather than the medical device or computing category signals how the company wants to be understood. The BCI itself is the data collection instrument; the long-term commercial value, in Synchron’s framing, sits in the neural data and the models trained on it. The question is whether that data moat proves defensible. Other BCI companies, including Neuralink and Blackrock Neurotech, are accumulating their own neural recordings as their trial cohorts grow. The difference so far is that Synchron has been the most explicit about treating the data as a product layer, not just a research byproduct.

The company has raised over $200 million, including a Series D round, and has implanted its Stentrode in more than fifty patients across clinical trials in the United States and Australia. The endovascular approach avoids craniotomy, which lowers surgical risk and has contributed to a safety record with no serious adverse events reported to date.

Whether the neural data platform model translates into revenue remains to be seen. Foundation models require scale, and twenty patient-years of data is substantial for the BCI field but modest by the standards of AI training generally. Synchron’s bet is that neural data is scarce enough and hard enough to collect that even a relatively small dataset confers a meaningful advantage, provided the company can maintain its lead in patient enrolment and continuous recording time.